Skip to main content
Clinical Trials/NL-OMON36192
NL-OMON36192CompletedPhase 4

Oral Versus Intravenous Dexamethasone in Community-acquired pneumonia study - OVID study

Sint Antonius Ziekenhuis0 sites30 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
30

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • - Aged 18 years and older
  • - Presenting to the emergency room with suspected pneumonia (to be confirmed within 24 hours from admission)
  • - Pneumonia is defined as a new or progressive infiltrate on a chest X-ray plus at least two of the following criteria: cough, sputum production, temperature >38°C or <35°C, ausculatory findings consistent with pneumonia, leucocytosis or leucopenia (>10 g/l, <4 g/l or >10% rods in leucocyte differentiation), C-reactive protein >3 times the upper normal limit
  • - Corticosteroid naive at time of presentation

Exclusion Criteria

  • - Patients needing corticosteroid treatment above study medication
  • - Failure to obtain written consent to participate
  • - Patients using fenytoine, barbiturates, rifampicine, erythromycin, clarithromycine, aprepitant, colchicine, everolimus, itraconazol, ketoconazole, pazopamib, tipranavir, vinorelbin
  • - Moribund patients (defined as expected to die within 24 hours)
  • - Patients with proven or suspected allergy to dexamethasone
  • - Patient not capable of taking tablets orally

Investigators

Similar Trials